|
시장보고서
상품코드
1907932
심근 허혈 시장 : 질환 유형별, 약제 클래스별, 투여 경로별, 약제 유형별, 최종 사용자별, 유통 채널별, 지역별Myocardial Ischemia Market, By Disease Type, By Drug Class, By Route of Administration,By Drug Type, By End User, By Distribution Channel, By Geography |
||||||
심근 허혈 시장은 2025년 47억 2,000만 달러로 평가되었고, 2032년까지 79억 8,000만 달러에 이를 것으로 예측됩니다. 2025-2032년 연평균 복합 성장률(CAGR) 7.8%로 성장할 것으로 전망되고 있습니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 시장 규모(2025년) | 47억 2,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측 기간 CAGR(2025-2032년) | 7.80% | 예측 금액(2032년) | 79억 8,000만 달러 |
세계의 심근 허혈 시장은 심혈관 치료 분야에서 중요한 부문을 차지하고 있으며 세계의 주요 사망 및 이환 원인 중 하나를 다루고 있습니다. 관상 동맥 폐색과 경련으로 인한 심근로의 혈류 감소를 특징으로 하는 심근 허혈은 안정 협심증에서 급성 관상 증후군에 이르기까지 전 세계 수백만 명의 환자에게 영향을 미칩니다. 이 시장은 항혈소판제, β차단제, ACE 억제제, 스타틴 등 약물 요법에 더해 경피적 관상동맥 인터벤션(PCI)이나 관상동맥 우회 이식술(CABG) 등 선진적인 개입 치료를 포함한 다양한 치료 개입을 망라하고 있습니다.
당뇨병, 고혈압, 비만, 운동 부족 등 심혈관 위험 인자 증가 추세와 세계의 고령화가 결합되어 대상 환자층은 크게 확대되고 있습니다. 게다가 진단 수법, 약물전달 시스템, 저침습 수술 기술에 있어서 기술 진보가 치료 패러다임을 혁신해, 시장 성장을 견인하고 있습니다. 신규 치료 표적, 맞춤형 의료 접근법, 치료 성과를 향상시키면서 헬스케어 비용을 삭감하는 병용 요법에 초점을 맞춘 활발한 연구개발 활동도 시장에 호영향을 가져오고 있습니다.
시장 역학
세계의 심근 허혈 시장은 궤도를 형성하는 몇 가지 주요 촉진요인에 의해 견인되고 있습니다. 주요 성장 요인은 심혈관 질환의 세계 부담 증가로 인한 것이며, 심근 허혈은 심장 관련 입원 및 헬스케어 지출의 중요한 부분을 차지하고 있습니다. 특히 개발도상국에서 당뇨병, 고혈압, 지질이상증, 흡연 등 생활습관과 관련된 위험요인의 유병률 상승이 환자층을 크게 확대시키고 있습니다.
또한 진단 영상 기술, 바이오마커 검출, 치료 개입 등의 기술 혁신으로 조기 발견과 치료 효과가 향상되어 시장의 보급을 촉진하고 있습니다. 서방형 약물 및 병용 요법을 포함한 신규 약물 제제의 개발은 환자의 복약 준수율과 임상 결과를 개선했습니다. 그러나 시장에는 성장세를 저해할 수 있는 현저한 제약이 존재합니다.
고도의 개입 치료 및 만성 질환 치료제와 관련된 고가의 치료 비용은 특히 헬스케어 자원이 제한된 의료 시스템에서 중요한 장벽이 되었습니다. 의료기기 승인 및 의약품 개발을 규제하는 엄격한 프레임워크는 승인까지 장기화하고 다량의 개발 비용을 초래합니다. 또한 전문 지식 및 인프라를 필요로 하는 심혈관 케어의 복잡성은 헬스케어 서비스가 없는 지역에서 시장 침투를 제한합니다. 블록버스터급 심혈관 치료제의 특허 만료는 제네릭 의약품과의 경쟁을 격화시키고 기존 기업의 수익원에 압력을 가하고 있습니다.
이러한 과제가 있는 한편, 경제 성장 및 헬스 케어 인프라 정비가 진행되는 신흥 시장에는 큰 기회가 존재합니다. 예방 심장 병학과 위험 계층화에 대한 관심 증가는 진단 및 모니터링 기술에 새로운 잠재력을 제공합니다. 디지털 건강 플랫폼, 원격 의료, 인공지능(AI) 용도 기술의 발전은 환자 관리 개선 및 치료 최적화에 기여할 수 있습니다.
게다가, 유전자 프로파일링 및 바이오마커 식별에 근거한 개인화된 의료 및 정밀 치료에 대한 관심 증가는 시장 확대를 향한 유망한 새로운 영역을 나타냅니다.
이 보고서의 주요 특징
- 이 보고서는 세계의 심근 허혈 시장을 상세하게 분석하여 2024년을 기준 연도로 한 예측 기간(2025-2032년) 시장 규모 및 CAGR을 제공합니다.
- 또한 각 부문의 잠재적인 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인 및 억제요인과 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요기업이 채용하는 경쟁 전략 등에 관한 중요한 인사이트도 제공합니다.
- 세계 심근 허혈 시장의 주요 기업 프로파일은 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등 다음 매개 변수를 기반으로 게시됩니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자 및 기업 경영진은 향후 제품 출시, 제휴, 시장 확대, 마케팅 전술에 대한 충분한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
- '세계의 심근 허혈 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 지원합니다.
- 이해관계자는 세계의 심근허혈 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적 및 전제조건
- 분석 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의 및 범위
- 주요 요약
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 출시 및 승인
- PEST 분석
- Porter's Five Forces 분석
- 기업 합병 및 인수(M&A) 시나리오
- 업계 동향
제4장 세계의 심근 허혈 시장 : 질환 유형별(2020-2032년)
- 안정 협심증
- 불안정 협심증
- 무증상성 심근허혈
- 혈관 경련성(프린츠 메탈) 협심증
- 미세혈관허혈
제5장 세계의 심근 허혈 시장 : 약제 클래스별(2020-2032년)
- 항협심증제(예 : 니트로글리세린, 이소소르비드 모노니트레이트)
- 항혈소판제(예 : 아스피린, 클로피도그렐, 치카그렐롤)
- 항응고제(예 : 헤파린, 에녹사파린, 아픽사반)
- β 차단제(예 : 메토프롤롤, 아테놀롤, 카베지롤)
- ACE 억제제(예 : 라미프릴, 리시노프릴, 에나라프릴)
- 안지오텐신 II 수용체 길항제(예 : 로사르탄, 발사르탄, 테르미사르탄)
- 칼슘 채널 차단제(예 : 암로디핀, 지르티아젬, 베라파밀)
- 질산염계 약제(예 : 니트로글리세린 스프레이, 이소소르비도디니트레이트)
- 스타틴계 약제(예 : 아토르바스타틴, 로스바스타틴, 심바스타틴)
- 지연 나트륨 전류 억제제 및 라놀라진(예 : 라놀라진)
- 혈전 용해제(예 : 알테프라제, 테넥테프라제, 스트렙토키나아제)
제6장 세계의 심근 허혈 시장 : 투여 경로별(2020-2032년)
- 경구
- 비경구
제7장 세계의 심근 허혈 시장 : 약제 유형별(2020-2032년)
- 브랜드 의약품
- 제네릭
제8장 세계의 심근 허혈 시장 : 최종 사용자별(2020-2032년)
- 병원
- 심장 전문 클리닉
- 진단센터
- 외래수술센터(ASC)
- 연구기관 및 학술기관
제9장 세계의 심근허혈 시장 : 유통 채널별(2020-2032년)
- 병원 약국
- 소매 약국
- 온라인 약국
제10장 세계의 심근 허혈 시장 : 지역별(2020-2032년)
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카 국가
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동 국가
- 아프리카
- 남아프리카
- 북아프리카
- 중앙 아프리카
제11장 경쟁 구도
- Pfizer Inc
- AstraZeneca PLC
- Bayer AG
- Novartis AG
- Merck and Co Inc
- Bristol-Myers Squibb Company
- Sanofi SA
- Daiichi Sankyo Company Limited
- Gilead Sciences Inc
- Johnson and Johnson
- Amgen Inc
- Boehringer Ingelheim
- Mylan NV
- Teva Pharmaceutical Industries Ltd
- GlaxoSmithKline PLC
제12장 애널리스트의 제안
- 기회
- 애널리스트의 견해
- 일관된 기회 지도(COM)
제13장 참고문헌 및 분석 방법
- 참고문헌
- 분석 방법
- Coherent Market Insights에 대해
Myocardial Ischemia Market is estimated to be valued at USD 4.72 Bn in 2025 and is expected to reach USD 7.98 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.8% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 4.72 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.80% | 2032 Value Projection: | USD 7.98 Bn |
The global myocardial ischemia market represents a critical segment within the cardiovascular therapeutics landscape, addressing one of the leading causes of mortality and morbidity worldwide. Myocardial ischemia, characterized by reduced blood flow to the heart muscle due to coronary artery obstruction or spasm, affects millions of patients globally and encompasses conditions ranging from stable angina to acute coronary syndromes. The market encompasses diverse therapeutic interventions including pharmacological treatments such as antiplatelet agents, beta-blockers, ACE inhibitors, and statins, alongside advanced interventional procedures like percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG).
The increasing prevalence of cardiovascular risk factors including diabetes, hypertension, obesity, and sedentary lifestyles, coupled with an aging global population, has significantly expanded the addressable patient population. Furthermore, technological advancements in diagnostic modalities, drug delivery systems, and minimally invasive surgical techniques have revolutionized treatment paradigms, driving market growth. The market also benefits from robust research and development activities focused on novel therapeutic targets, personalized medicine approaches, and combination therapies that improve patient outcomes while reducing healthcare costs.
Market Dynamics
The global myocardial ischemia market is propelled by several key drivers that continue to shape its trajectory. The primary growth driver stems from the escalating global burden of cardiovascular diseases, with myocardial ischemia representing a significant portion of cardiac-related hospitalizations and healthcare expenditures. Rising prevalence of lifestyle-associated risk factors including diabetes mellitus, hypertension, dyslipidemia, and smoking, particularly in developing economies, has expanded the patient pool substantially.
Additionally, technological innovations in diagnostic imaging, biomarker detection, and therapeutic interventions have enhanced early detection and treatment efficacy, driving market adoption. The development of novel drug formulations, including extended-release medications and combination therapies, has improved patient compliance and clinical outcomes. However, the market faces notable restraints that could impede growth momentum.
High treatment costs associated with advanced interventional procedures and chronic medication regimens pose significant barriers, particularly in resource-constrained healthcare systems. Stringent regulatory frameworks governing medical device approvals and pharmaceutical development create lengthy approval timelines and substantial development costs. Additionally, the complexity of cardiovascular care requiring specialized expertise and infrastructure limits market penetration in underserved regions. Patent expirations of blockbuster cardiovascular medications have intensified generic competition, pressuring revenue streams for established players.
Despite these challenges, substantial opportunities exist within emerging markets experiencing economic growth and healthcare infrastructure development. The increasing focus on preventive cardiology and risk stratification presents opportunities for diagnostic and monitoring technologies. Advances in digital health platforms, telemedicine, and artificial intelligence applications offer potential for improving patient management and treatment optimization.
Furthermore, the growing emphasis on personalized medicine and precision therapeutics based on genetic profiling and biomarker identification represents a promising frontier for market expansion.
Key Features of the Study
- This report provides in-depth analysis of the global myocardial ischemia market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global myocardial ischemia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc, AstraZeneca PLC, Bayer AG, Novartis AG, Merck and Co Inc, Bristol-Myers Squibb Company, Sanofi SA, Daiichi Sankyo Company Limited, Gilead Sciences Inc, Johnson and Johnson, Amgen Inc, Boehringer Ingelheim, Mylan NV, Teva Pharmaceutical Industries Ltd, and GlaxoSmithKline PLC
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global myocardial ischemia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global myocardial ischemia market
Market Segmentation
- Disease Type Insights (Revenue, USD Bn, 2020 - 2032)
- Stable Angina
- Unstable Angina
- Silent Myocardial Ischemia
- Vasospastic (Prinzmetal) Angina
- Microvascular Ischemia
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Anti-Anginal Agents (e.g., nitroglycerin, isosorbide mononitrate)
- Antiplatelet Agents (e.g., aspirin, clopidogrel, ticagrelor)
- Anticoagulants (e.g., heparin, enoxaparin, apixaban)
- Beta-Blockers (e.g., metoprolol, atenolol, carvedilol)
- ACE Inhibitors (e.g., ramipril, lisinopril, enalapril)
- Angiotensin II Receptor Blockers (e.g., losartan, valsartan, telmisartan)
- Calcium Channel Blockers (e.g., amlodipine, diltiazem, verapamil)
- Nitrates (e.g., nitroglycerin spray, isosorbide dinitrate)
- Statins (e.g., atorvastatin, rosuvastatin, simvastatin)
- Late Sodium Current Inhibitors/Ranolazine (e.g., ranolazine)
- Thrombolytics (e.g., alteplase, tenecteplase, streptokinase)
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
- Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Branded
- Generic
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Cardiac Specialty Clinics
- Diagnostic Centers
- Ambulatory Surgical Centers
- Research and Academic Institutes
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc
- AstraZeneca PLC
- Bayer AG
- Novartis AG
- Merck and Co Inc
- Bristol-Myers Squibb Company
- Sanofi SA
- Daiichi Sankyo Company Limited
- Gilead Sciences Inc
- Johnson and Johnson
- Amgen Inc
- Boehringer Ingelheim
- Mylan NV
- Teva Pharmaceutical Industries Ltd
- GlaxoSmithKline PLC
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Myocardial Ischemia Market, By Disease Type
- Global Myocardial Ischemia Market, By Drug Class
- Global Myocardial Ischemia Market, By Route of Administration
- Global Myocardial Ischemia Market, By Drug Type
- Global Myocardial Ischemia Market, By End User
- Global Myocardial Ischemia Market, By Distribution Channel
- Global Myocardial Ischemia Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Myocardial Ischemia Market, By Disease Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Stable Angina
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Unstable Angina
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Silent Myocardial Ischemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Vasospastic (Prinzmetal) Angina
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Microvascular Ischemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Myocardial Ischemia Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Anti-Anginal Agents (e.g., nitroglycerin, isosorbide mononitrate)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Antiplatelet Agents (e.g., aspirin, clopidogrel, ticagrelor)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Anticoagulants (e.g., heparin, enoxaparin, apixaban)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Beta-Blockers (e.g., metoprolol, atenolol, carvedilol)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- ACE Inhibitors (e.g., ramipril, lisinopril, enalapril)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Angiotensin II Receptor Blockers (e.g., losartan, valsartan, telmisartan)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Calcium Channel Blockers (e.g., amlodipine, diltiazem, verapamil)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Nitrates (e.g., nitroglycerin spray, isosorbide dinitrate)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Statins (e.g., atorvastatin, rosuvastatin, simvastatin)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Late Sodium Current Inhibitors/Ranolazine (e.g., ranolazine)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Thrombolytics (e.g., alteplase, tenecteplase, streptokinase)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Myocardial Ischemia Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Myocardial Ischemia Market, By Drug Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Myocardial Ischemia Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cardiac Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Diagnostic Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Research and Academic Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Myocardial Ischemia Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Myocardial Ischemia Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Disease Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck and Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Daiichi Sankyo Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson and Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan NV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
